Literature DB >> 16541471

OX40 (CD134) engagement drives differentiation of CD4+ T cells to effector cells.

Cortny A Huddleston1, Andrew D Weinberg, David C Parker.   

Abstract

Naive, CD4+ T cells proliferate extensively but fail to differentiate when they are transferred into unirradiated recipients that express alloantigen or transgenic antigen on all MHC class II+ cells. Addition of an agonist antibody to OX40 (CD134), a costimulatory TNF receptor family member expressed on activated CD4+ T cells, enables the proliferating T cells to accumulate as differentiated effector cells and kill the host animals. The donor T cells from anti-OX40-treated animals express high levels of IL-2R alpha (CD25) and acquire the ability to secrete IFN-gamma when stimulated with IL-12 and IL-18. OX40 promotes differentiation by 48 h in T cell priming, before changes in Bcl-2 expression or cell recovery become apparent. We found that a Bcl-2 transgene or deficiency in Fas or TNFR1 failed to influence accumulation of differentiated donor cells, and found larger changes in expression of cytokine and cytokine receptor genes than in survival genes. Accumulation of differentiated CD4+ effector T cells is initiated directly through OX40, but some OX40-deficient donor cells can gain effector function as bystanders to OX40+/+ cells. Taken together, these data suggest that CD4+ T cell differentiation to effector function is an important effect of OX40 engagement under conditions of ubiquitous antigen presentation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16541471     DOI: 10.1002/eji.200535637

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  23 in total

Review 1.  Signaling through OX40 enhances antitumor immunity.

Authors:  Shawn M Jensen; Levi D Maston; Michael J Gough; Carl E Ruby; William L Redmond; Marka Crittenden; Yuhuan Li; Sachin Puri; Christian H Poehlein; Nick Morris; Magdalena Kovacsovics-Bankowski; Tarsem Moudgil; Chris Twitty; Edwin B Walker; Hong-Ming Hu; Walter J Urba; Andrew D Weinberg; Brendan Curti; Bernard A Fox
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

2.  Antiapoptotic Clone 11-Derived Peptides Induce In Vitro Death of CD4+ T Cells Susceptible to HIV-1 Infection.

Authors:  Anastassia Mikhailova; José Carlos Valle-Casuso; Annie David; Valérie Monceaux; Stevenn Volant; Caroline Passaes; Amal Elfidha; Michaela Müller-Trutwin; Jean-Luc Poyet; Asier Sáez-Cirión
Journal:  J Virol       Date:  2020-07-01       Impact factor: 5.103

3.  CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors.

Authors:  Xupeng Ge; Julia Brown; Megan Sykes; Vassiliki A Boussiotis
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

4.  Optimal CD4 T cell priming after LPS-based adjuvanticity with CD134 costimulation relies on CXCL9 production.

Authors:  Paurvi Shinde; Wenhai Liu; Antoine Ménoret; Andrew D Luster; Anthony T Vella
Journal:  J Leukoc Biol       Date:  2017-04-21       Impact factor: 4.962

5.  Cyclosporine-resistant, Rab27a-independent mobilization of intracellular preformed CD40 ligand mediates antigen-specific T cell help in vitro.

Authors:  Yoshinobu Koguchi; Jennifer L Gardell; Timothy J Thauland; David C Parker
Journal:  J Immunol       Date:  2011-06-15       Impact factor: 5.422

6.  Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain.

Authors:  Nicholas P Morris; Carmen Peters; Ryan Montler; Hong-Ming Hu; Brendan D Curti; Walter J Urba; Andrew D Weinberg
Journal:  Mol Immunol       Date:  2007-03-19       Impact factor: 4.407

7.  Peripheral CD4(+) T-cell tolerance is induced in vivo by rare antigen-bearing B cells in follicular, marginal zone, and B-1 subsets.

Authors:  Susan E Murray; Katelynne Gardner Toren; David C Parker
Journal:  Eur J Immunol       Date:  2013-05-08       Impact factor: 5.532

8.  Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus.

Authors:  Sebastian Dolff; Daniel Quandt; Benjamin Wilde; Thorsten Feldkamp; Fan Hua; Xin Cai; Christof Specker; Andreas Kribben; Cees G M Kallenberg; Oliver Witzke
Journal:  Arthritis Res Ther       Date:  2010-07-23       Impact factor: 5.156

9.  Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.

Authors:  David J Messenheimer; Shawn M Jensen; Michael E Afentoulis; Keith W Wegmann; Zipei Feng; David J Friedman; Michael J Gough; Walter J Urba; Bernard A Fox
Journal:  Clin Cancer Res       Date:  2017-08-28       Impact factor: 12.531

Review 10.  The role of OX40-mediated co-stimulation in T-cell activation and survival.

Authors:  William L Redmond; Carl E Ruby; Andrew D Weinberg
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.